Related content

Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease

By Blum Shany   Milman Uzi   Shapira Chen   Levy Andrew P  

Pharmacogenomics, Vol. 9, Iss. 8, 2008-08 ,pp. : 989-991

Future Medicine

Access to resources Recommend Favorite

The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice

By Voors Adriaan A.   Veldhuisen Dirk J.   Gilst Wiek H.  

Cardiovascular Drugs and Therapy, Vol. 20, Iss. 1, 2006-02 ,pp. : 69-73

Springer Publishing Company

Access to resources Recommend Favorite

Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 11, 2002-11 ,pp. : 1543-1556

Informa Healthcare

Access to resources Recommend Favorite

Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype

By Blum Shany   Vardi Moshe   Brown Jonathan B   Russell Allen   Milman Uzi   Shapira Chen   Levy Nina S   Miller-Lotan Rachel   Asleh Rabea   Levy Andrew P  

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 675-684

Future Medicine

Access to resources Recommend Favorite

ACE Cardiovascular Protection: EUROPA versus HOPE

By Boos Christopher J.   Dawes Matthew  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 3, 2004-05 ,pp. : 179-180

Springer Publishing Company

Access to resources Recommend Favorite